Norstella introduces NorstellaLinQ, the biopharma industry’s first fully integrated data asset

Published on October 8, 2024

NEW YORK – October 8, 2024 - Today, Norstella unveiled NorstellaLinQ, the biopharma industry’s first and only fully integrated data asset combining both real-world data (RWD) — including open and closed claims, lab results and structured and unstructured electronic medical records (EMR) — with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data.

Continue reading on website
Other news

Addressing Antibody-Drug Conjugate Development Challenges

October 4, 2024
Abzena’s Scientific Leader and Senior Vice President, Petra Dieterich Ph.D., features in a new article on Biocompare.As part of the articles ‘Addressing Antibody-Drug Conjugate Development Challenges’ feature, Petra provided her thoughts on how ADC products still face existential issues like off-target toxicity, tumor heterogeneity, and unpredictable pharmacokinetics (PK).“Tumor heterogeneity lead

The current & future impact of AI on pharmaceutical R&D

October 9, 2024
As the life sciences industry moves away from the early stages of artificial intelligence (AI) adoption, it is imperative that we keep a close eye on how this landscape is changing as more and more paradigms are affected by AI usage. Norstella goes beyond the hype to address real-world implications of advanced technologies that will […]